Iovance Biotherapeutics Inc

Latest Results (01.03.2026):

Iovance Biotherapeutics Inc — third quarter of 2025: The company reported Q3 2025 product revenue of about $67.5 million (reported as ~ $68M), a 13% sequential increase, with gross margin improving to 43%. Iovance posted a Q3 net loss of $91.3 million (GAAP) or $(0.25) per share, held about $307 million in cash, investments and restricted cash at September 30, 2025, and reaffirmed full‑year 2025 revenue guidance of $250–$300 million while projecting cash to fund operations into Q2 2027.

Topline and revenue growth

Q3 product revenue totaled $67.455M (up 13% sequentially). Revenue mix was ~$58M U.S. Amtagvi and ~$10M global Proleukin.

Margin improvement and cost optimization

Gross margin rose to 43% with cost of sales of ~$38.5M, reflecting improved execution and initial benefits from cost‑optimization initiatives; additional operational excellence actions are underway.

Profitability and expenses

Loss from operations in Q3 was $94.9M; GAAP net loss was $91.253M and GAAP net loss per share was $(0.25). Major expense lines included R&D $75.2M and SG&A $34.6M for the quarter.

Cash position and runway

Cash, cash equivalents, investments and restricted cash totaled ~$307M at 9/30/2025. Management expects the current cash position, combined with expense reductions, to fund operations into Q2 2027.

Guidance

Full‑year 2025 revenue guidance was reaffirmed at $250–$300M, noted as the first full calendar year of Amtagvi sales.

Commercial launch and access

U.S. launch progress: >80 authorized treatment centers activated across ~40 states, covering ~95% of patients within a two‑hour drive; community ATCs are beginning to treat patients and specialty pharmacy support agreements (InspiroGene/McKesson) were announced to broaden access.

Manufacturing and operational metrics

Manufacturing turnaround improved to an average of 32 days from inbound to return shipment to ATCs. Iovance plans to centralize manufacturing at its Iovance Cell Therapy Center (iCTC) in early 2026 to reduce external manufacturing spend and further improve margins.

Regulatory and global expansion

Health Canada approved Amtagvi in August 2025 (first approval outside the U.S.). Potential approvals in the U.K. and Australia are anticipated in H1 2026 and Switzerland in 2027; EMA strategy is being finalized for EU authorization.

Clinical pipeline — lifileucel and next‑gen programs

IOV‑LUN‑202 (lifileucel in previously treated nonsquamous NSCLC) showed interim ORR 26% with median duration of response not reached after >25 months; enrollment expected to complete in 2026 to support a supplemental BLA and potential 2027 launch. Other readouts: IOV‑END‑201 initial results on track for early 2026, TILVANCE‑301 accrual ongoing, and several next‑generation programs (IOV‑4001, IOV‑3001, IOV‑5001) progressing toward data readouts, INDs or Phase 2 in 2026.